Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A.

J Clin Oncol. 2019 Aug 5:JCO1901461. doi: 10.1200/JCO.19.01461. [Epub ahead of print]

PMID:
31381464
2.

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH.

Wang TF, Zwicker JI, Ay C, Pabinger I, Falanga A, Antic D, Noble S, Khorana AA, Carrier M, Meyer G.

J Thromb Haemost. 2019 Jul 15. doi: 10.1111/jth.14564. [Epub ahead of print] No abstract available.

PMID:
31353841
3.

Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients.

Park DY, Khorana AA.

Semin Thromb Hemost. 2019 Jul 26. doi: 10.1055/s-0039-1693474. [Epub ahead of print]

PMID:
31350735
4.

Predicting outcomes in patients with cancer and atrial fibrillation.

Gutierrez A, Patell R, Rybicki L, Khorana AA.

Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719860676. doi: 10.1177/1753944719860676.

5.

Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis.

Roopkumar J, Khorana AA.

Cancer Treat Res. 2019;179:55-68. doi: 10.1007/978-3-030-20315-3_4.

PMID:
31317480
6.

Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update Summary.

Khorana AA, McKernin SE, Katz MHG.

J Oncol Pract. 2019 Aug;15(8):454-457. doi: 10.1200/JOP.19.00253. Epub 2019 Jul 15. No abstract available.

PMID:
31306038
7.

Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. A systematic review and meta-analysis.

Delluc A, Miranda S, den Exter P, Louzada M, Alatri A, Ahn S, Monreal M, Khorana A, Huisman MV, Wells PS, Carrier M.

Haematologica. 2019 Jul 4. pii: haematol.2019.222828. doi: 10.3324/haematol.2019.222828. [Epub ahead of print]

8.

Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update.

Khorana AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravek C, Mumber M, Schulick R, Zeh HJ, Katz MHG.

J Clin Oncol. 2019 Aug 10;37(23):2082-2088. doi: 10.1200/JCO.19.00946. Epub 2019 Jun 10.

PMID:
31180816
9.

Preventing Venous Thromboembolism in Patients with Cancer. Reply.

Khorana AA, Mones J, Soff GA.

N Engl J Med. 2019 May 30;380(22):2181. doi: 10.1056/NEJMc1904003. No abstract available.

PMID:
31141646
10.

Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.

Streiff M, Milentijevic D, McCrae KR, Laliberté F, Lejeune D, Lefebvre P, Schein J, Khorana AA.

J Med Econ. 2019 Jun 12:1-7. doi: 10.1080/13696998.2019.1620752. [Epub ahead of print]

PMID:
31106638
11.

Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting.

Kunapareddy G, Switzer B, Jain P, Conces M, Chen YW, Patel B, Patel S, Pinnamaneni P, Pohlman B, Angelini DE, McCrae KR, Khorana AA.

Res Pract Thromb Haemost. 2019 Jan 28;3(2):226-233. doi: 10.1002/rth2.12176. eCollection 2019 Apr.

12.

Bleeding incidence and risk factors among cancer patients treated with anticoagulation.

Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA.

Am J Hematol. 2019 Jul;94(7):780-785. doi: 10.1002/ajh.25494. Epub 2019 May 16.

PMID:
31006890
13.

Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database study.

AlHilli MM, Elson P, Rybicki L, Khorana AA, Rose PG.

Gynecol Oncol. 2019 Jun;153(3):511-516. doi: 10.1016/j.ygyno.2019.03.244. Epub 2019 Apr 15.

PMID:
31000472
14.

Correction: Time to initial cancer treatment in the United States and association with survival over time: An observational study.

Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ.

PLoS One. 2019 Apr 4;14(4):e0215108. doi: 10.1371/journal.pone.0215108. eCollection 2019.

15.

Does Sidedness Matter in Unresectable Colorectal Cancer?

Kamath SD, Khorana AA.

Ann Surg Oncol. 2019 Jun;26(6):1588-1591. doi: 10.1245/s10434-019-07315-w. Epub 2019 Mar 18. No abstract available.

PMID:
30887371
16.

A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.

Ramanathan RK, Thomas GW, Khorana AA, Shah S, Zhou C, Wong S, Cole G Jr, James D, Gabrail NY.

Oncology. 2019;96(4):217-222. doi: 10.1159/000495988. Epub 2019 Mar 7.

17.

Time to initial cancer treatment in the United States and association with survival over time: An observational study.

Khorana AA, Tullio K, Elson P, Pennell NA, Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM, Monteleone EE, Wei W, Hobbs B, Bolwell BJ.

PLoS One. 2019 Mar 1;14(3):e0213209. doi: 10.1371/journal.pone.0213209. eCollection 2019. Erratum in: PLoS One. 2019 Apr 4;14(4):e0215108.

18.

If Trousseau had a stroke.

Khorana AA.

Blood. 2019 Feb 21;133(8):769-770. doi: 10.1182/blood-2019-01-894261. No abstract available.

PMID:
30792219
19.

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators.

N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.

PMID:
30786186
20.

Duration of anticoagulant therapy and VTE recurrence in patients with cancer.

Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J.

Support Care Cancer. 2019 Feb 8. doi: 10.1007/s00520-019-4661-3. [Epub ahead of print]

PMID:
30734088
21.

Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid.

Patel HK, Khorana AA.

Curr Oncol Rep. 2019 Feb 4;21(2):18. doi: 10.1007/s11912-019-0767-5. Review.

PMID:
30715628
22.

Evaluating Susceptibility to Pancreatic Cancer: ASCO Clinical Practice Provisional Clinical Opinion Summary.

Stoffel EM, McKernin SE, Khorana AA.

J Oncol Pract. 2019 Feb;15(2):108-111. doi: 10.1200/JOP.18.00629. Epub 2018 Dec 27. No abstract available.

PMID:
30589608
23.

The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation.

Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberté F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

Am J Hematol. 2019 Feb;94(2):E58-E61. doi: 10.1002/ajh.25361. Epub 2018 Dec 18. No abstract available.

24.

Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.

Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C, Nagarajan A, Petersen GM, Simeone DM, Yurgelun M, Khorana AA.

J Clin Oncol. 2019 Jan 10;37(2):153-164. doi: 10.1200/JCO.18.01489. Epub 2018 Nov 20.

PMID:
30457921
25.

Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review.

Samuelson Bannow BR, Lee AYY, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M.

Res Pract Thromb Haemost. 2018 Jun 19;2(4):664-669. doi: 10.1002/rth2.12111. eCollection 2018 Oct.

26.

Artificial intelligence for cancer-associated thrombosis risk assessment - Author's reply.

Khorana AA.

Lancet Haematol. 2018 Sep;5(9):e391-e392. doi: 10.1016/S2352-3026(18)30118-2. No abstract available.

PMID:
30172344
27.

Adjuvant Treatment in Potentially Curable Pancreatic Cancer: Need to Include Tumor Location in the Equation?

Mukhija D, Sohal DPS, Khorana AA.

Pancreas. 2018 Sep;47(8):e50-e52. doi: 10.1097/MPA.0000000000001125. No abstract available.

PMID:
30113430
28.

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.

Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O'Connell C, Carrier M.

J Thromb Haemost. 2018 Sep;16(9):1891-1894. doi: 10.1111/jth.14219. Epub 2018 Jul 19. No abstract available.

PMID:
30027649
29.

Do patients with pancreatic body or tail cancer benefit from adjuvant therapy?A cohort study.

Sohal DPS, Tullio K, Khorana AA.

Surg Oncol. 2018 Jun;27(2):245-250. doi: 10.1016/j.suronc.2018.05.008. Epub 2018 May 7.

PMID:
29937178
30.

An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution".

Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Lejeune D, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana AA.

Am J Hematol. 2018 Sep;93(9):E225-E227. doi: 10.1002/ajh.25165. Epub 2018 Aug 7. No abstract available.

PMID:
29905381
31.

Simplicity versus complexity: an existential dilemma as risk tools evolve.

Khorana AA.

Lancet Haematol. 2018 Jul;5(7):e273-e274. doi: 10.1016/S2352-3026(18)30067-X. Epub 2018 Jun 7. No abstract available. Erratum in: Lancet Haematol. 2018 Jun 15;:.

32.

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D.

J Clin Oncol. 2018 Aug 20;36(24):2545-2556. doi: 10.1200/JCO.2018.78.9636. Epub 2018 May 23.

PMID:
29791286
33.

Prevalence of Venous Thromboembolism Diagnosed in Emergency Department Visits by Cancer Patients and Associated Healthcare Resource Utilization in the United States.

Chen YW, Wang MJ, Khorana AA.

Am J Hematol. 2018 May 23. doi: 10.1002/ajh.25148. [Epub ahead of print] No abstract available.

34.

Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.

Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, Canin B, Cohen HJ, Holmes HM, Hopkins JO, Janelsins MC, Khorana AA, Klepin HD, Lichtman SM, Mustian KM, Tew WP, Hurria A.

J Clin Oncol. 2018 Aug 1;36(22):2326-2347. doi: 10.1200/JCO.2018.78.8687. Epub 2018 May 21.

35.

Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.

Samuelson Bannow BT, Lee A, Khorana AA, Zwicker JI, Noble S, Ay C, Carrier M.

J Thromb Haemost. 2018 Jun;16(6):1246-1249. doi: 10.1111/jth.14015. Epub 2018 May 8. No abstract available.

PMID:
29737593
36.

Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Riess H, Ay C, Bauersachs R, Becattini C, Beyer-Westendorf J, Cajfinger F, Chau I, Cohen AT, Khorana AA, Maraveyas A, Renni M, Young AM.

Oncologist. 2018 Jul;23(7):822-839. doi: 10.1634/theoncologist.2017-0473. Epub 2018 Apr 12. Review.

37.

Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.

Bauersachs R, Lee AYY, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, Khorana AA; CATCH Investigators.

Thromb Haemost. 2018 May;118(5):914-921. doi: 10.1055/s-0038-1641150. Epub 2018 Apr 4.

PMID:
29618162
38.

Multidisciplinary Conference and Clinical Management of Rectal Cancer.

Karagkounis G, Stocchi L, Lavery IC, Liska D, Gorgun E, Veniero J, Plesec T, Amarnath S, Khorana AA, Kalady MF.

J Am Coll Surg. 2018 May;226(5):874-880. doi: 10.1016/j.jamcollsurg.2018.01.056. Epub 2018 Mar 23.

PMID:
29580878
39.

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.

Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators.

J Thromb Haemost. 2018 Jun;16(6):1069-1077. doi: 10.1111/jth.14007. Epub 2018 Apr 17.

PMID:
29573330
40.

Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.

Khorana AA, Weitz JI.

Thromb Haemost. 2018 May;118(S 01):S23-S33. doi: 10.1160/TH17-09-0681. Epub 2018 Mar 22.

PMID:
29566417
41.

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.

Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J, Khorana AA.

Am J Hematol. 2018 May;93(5):664-671. doi: 10.1002/ajh.25059. Epub 2018 Feb 23.

42.

Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future.

Khorana AA, Francis CW.

Thromb Res. 2018 Apr;164 Suppl 1:S70-S76. doi: 10.1016/j.thromres.2018.01.036. Epub 2018 Jan 31. Review.

PMID:
29395243
43.

Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study.

Sohal DPS, Kuderer NM, Shepherd FA, Pabinger I, Agnelli G, Liebman HA, Meyer G, Kalady MF, McCrae K, Lyman GH, Khorana AA.

JNCI Cancer Spectr. 2017 Nov 28;1(1):pkx009. doi: 10.1093/jncics/pkx009. eCollection 2017 Sep.

44.

Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.

Berriochoa CA, Abdel-Wahab M, Leyrer CM, Khorana A, Matthew Walsh R, Kumar AMS.

J Dig Dis. 2017 Nov;18(11):642-649. doi: 10.1111/1751-2980.12551.

PMID:
29055078
45.

Determination of the impact of melanoma surgical timing on survival using the National Cancer Database.

Conic RZ, Cabrera CI, Khorana AA, Gastman BR.

J Am Acad Dermatol. 2018 Jan;78(1):40-46.e7. doi: 10.1016/j.jaad.2017.08.039. Epub 2017 Oct 17.

46.

Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation.

Patell R, Gutierrez A, Rybicki L, Khorana AA.

Am J Cardiol. 2017 Dec 15;120(12):2182-2186. doi: 10.1016/j.amjcard.2017.08.038. Epub 2017 Sep 20.

PMID:
29033049
47.

Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).

Kuderer NM, Poniewierski MS, Culakova E, Lyman GH, Khorana AA, Pabinger I, Agnelli G, Liebman HA, Vicaut E, Meyer G, Shepherd FA.

Oncologist. 2018 Feb;23(2):247-255. doi: 10.1634/theoncologist.2017-0205. Epub 2017 Sep 26.

48.

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.

Khorana AA, Vadhan-Raj S, Kuderer NM, Wun T, Liebman H, Soff G, Belani C, O'Reilly EM, McBane R, Eikelboom J, Damaraju CV, Beyers K, Dietrich F, Kakkar AK, Riess H, Peixoto RD, Lyman GH.

Thromb Haemost. 2017 Nov 1;117(11):2135-2145. doi: 10.1160/TH17-03-0171. Epub 2017 Sep 21.

49.

Identifying predictors for bleeding in hospitalized cancer patients: A cohort study.

Patell R, Gutierrez A, Rybicki L, Khorana AA.

Thromb Res. 2017 Oct;158:38-43. doi: 10.1016/j.thromres.2017.08.005. Epub 2017 Aug 12.

PMID:
28820967
50.

Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.

Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S.

Clin Ther. 2017 Jul;39(7):1396-1408. doi: 10.1016/j.clinthera.2017.05.357. Epub 2017 Jun 20.

PMID:
28645879

Supplemental Content

Loading ...
Support Center